Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan List

Showing results (21-30 of 72) with videos related to

Pageof 8
Sort By:
Current Opinion in Hematology|January 27, 2007
The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromesMagda Melchert, Vishakha Kale, Alan List
Journal of the American Geriatrics Society|April 10, 2023
Cell cycle arrest: A breakthrough in the supportive care of older cancer patientsClaire Falandry, Alan List, Lodovico Balducci
Leukemia|February 16, 2018
A decade of progress in myelodysplastic syndrome with chromosome 5q deletionAlan List, Benjamin L Ebert, Pierre Fenaux
Frontiers in Oncology|October 9, 2014
PP2A: The Achilles Heal in MDS with 5q DeletionDavid A Sallman, Sheng Wei, Alan List
The New England Journal of Medicine|October 30, 2014
Applying synthetic lethality for the selective targeting of cancerDonal P McLornan, Alan List, Ghulam J Mufti
European Journal of Haematology|December 23, 2018
Molecular pathogenesis of myelodysplastic syndromes with deletion 5qJung-Hoon Lee, Alan List, David A Sallman
Frontiers in Oncology|July 6, 2016
Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS PhenotypeDavid A Sallman, Thomas Cluzeau, Ashley A Basiorka, et al.
Leukemia & Lymphoma|January 31, 2008
Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairmentStefan Knop, Hermann Einsele, Ralf Bargou, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 14, 2017
SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic SyndromesDavid A Sallman, Tiffany N Tanaka, Alan List, et al.
Cancer Genetics and Cytogenetics|November 26, 2008
Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testingClaudia Haferlach, Ulrike Bacher, Ramon Tiu, et al.
Pageof 8

Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
Current Opinion in Hematology|January 27, 2007
The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromesMagda Melchert, Vishakha Kale, Alan List
Journal of the American Geriatrics Society|April 10, 2023
Cell cycle arrest: A breakthrough in the supportive care of older cancer patientsClaire Falandry, Alan List, Lodovico Balducci
Leukemia|February 16, 2018
A decade of progress in myelodysplastic syndrome with chromosome 5q deletionAlan List, Benjamin L Ebert, Pierre Fenaux
Frontiers in Oncology|October 9, 2014
PP2A: The Achilles Heal in MDS with 5q DeletionDavid A Sallman, Sheng Wei, Alan List
The New England Journal of Medicine|October 30, 2014
Applying synthetic lethality for the selective targeting of cancerDonal P McLornan, Alan List, Ghulam J Mufti
European Journal of Haematology|December 23, 2018
Molecular pathogenesis of myelodysplastic syndromes with deletion 5qJung-Hoon Lee, Alan List, David A Sallman
Frontiers in Oncology|July 6, 2016
Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS PhenotypeDavid A Sallman, Thomas Cluzeau, Ashley A Basiorka, et al.
Leukemia & Lymphoma|January 31, 2008
Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairmentStefan Knop, Hermann Einsele, Ralf Bargou, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 14, 2017
SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic SyndromesDavid A Sallman, Tiffany N Tanaka, Alan List, et al.
Cancer Genetics and Cytogenetics|November 26, 2008
Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testingClaudia Haferlach, Ulrike Bacher, Ramon Tiu, et al.
Pageof 8